Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069650 | 0.88 | KCNH2 (0.37) | KCNH2DGAT1NR1I2 | |
| SCHEMBL13429785 | 0.87 | KCNH2 (0.37) | KCNH2P2RX3DGAT1NR1I2HCRTR2 | |
| SCHEMBL13424166 | 0.85 | KCNH2 (0.39) | KCNH2HPRT1TYMS | |
| SCHEMBL13429487 | 0.84 | MAOA (0.42) | KCNH2HPRT1HCRTR2HCRTR1 | |
| SCHEMBL9964851 | 0.83 | KCNH2 (0.51) | KCNH2DGAT1 | |
| SCHEMBL9964852 | 0.83 | KCNH2 (0.37) | KCNH2HPRT1TYMS | |
| SCHEMBL13430148 | 0.83 | KCNH2 (0.38) | KCNH2HPRT1TYMS | |
| SCHEMBL13429500 | 0.82 | KCNH2 (0.40) | KCNH2HPRT1TYMS | |
| SCHEMBL13430096 | 0.82 | KCNH2 (0.37) | KCNH2HPRT1 | |
| SCHEMBL13430069 | 0.80 | KCNH2 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | KCNH2 1295/4885HPRT1 279/4885TYMS 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.